MetaCap

Keros Therapeutics (KROS) vs Rocket Pharmaceuticals (RCKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rocket Pharmaceuticals (RCKT) has outperformed Keros Therapeutics (KROS) over the past year, losing 33.4% versus a loss of 36.3%. Over five years, KROS leads with a -80.2% price change compared with -91.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($217.7 million vs $217.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KROS-36.29%RCKT-33.45%
+87%+17%-54%
Nov 21, 20251 yearNov 20, 2026
KROS-81.48%RCKT-93.00%
+23%-38%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KROS versus RCKT key metrics
MetricKROSRCKT
Share price$11.08$1.95
Market cap$217.44M$217.74M
1-day change-2.72%-7.58%
YTD return-45.58%-44.44%
1-year return-36.29%-33.45%
5-year return-80.25%-91.76%
EPS (TTM)$-2.32$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$243.86M$0
Net income (latest FY)$87.01M$-223.12M
Operating margin27.71%—
Net margin35.68%—
52-week high$22.55$5.45
52-week low$8.98$1.94
Distance from 52-week high-50.86%-64.22%
Analyst consensusbuybuy
Avg. price target upside+78.97%+326.15%
Average volume196.50K1.90M
Shares outstanding19.62M111.66M
Employees87202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Keros Therapeutics

KROS stock →

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Rocket Pharmaceuticals

RCKT stock →

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees

KROS vs RCKT FAQ

Which is bigger, Keros Therapeutics or Rocket Pharmaceuticals?

Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $217.74M compared with $217.44M for Keros Therapeutics (KROS).

Which stock has performed better over the past year, KROS or RCKT?

RCKT returned -33.45% over the past 12 months, compared with -36.29% for KROS (price return, excluding dividends). Past performance does not predict future results.

Are Keros Therapeutics and Rocket Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons